Genticel

About:

Gentiel develops therapeutic vaccines for the prevention of cervical cancer in HPV infected women.

Top Investors: Andera Partners, Wellington Partners, Idinvest Partners, Amundi Private Equity Funds, InnoBio Fund

Description:

Genticel is a French clinical stage biotechnology company founded by Benedikt Timmerman in 2001 and focused on the development of innovative immunotherapies designed to treat virus infections and virus-induced diseases. Genticel aims to become a leader in immunotherapy in multiple indications, starting with HPV and HPV induced diseases such as cervical cancer.

Total Funding Amount:

$41.4M

Headquarters Location:

Paris, Ile-de-France, France

Founded Date:

2001-01-01

Founders:

Benedikt Timmerman

Number of Employees:

11-50

Last Funding Date:

2013-04-24

IPO Status:

Private

Industries: